Financial News
Latest News about NVS
Recent news which mentions NVS
From Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
February 24, 2025
From Benzinga
From Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
February 11, 2025
From Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
February 10, 2025
From Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
February 07, 2025
From Benzinga
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
February 03, 2025
From Motley Fool
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
January 31, 2025
From Benzinga
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
January 31, 2025
From Benzinga
Earnings Scheduled For January 31, 2025
January 31, 2025
From Benzinga
From Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
From Benzinga
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
From Benzinga
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
January 22, 2025
From Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
January 16, 2025
From Benzinga
From Benzinga
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
January 06, 2025
From Benzinga
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
December 30, 2024
From Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
December 19, 2024
From Benzinga
From Benzinga
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
December 06, 2024
From Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
December 03, 2024
From Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
December 02, 2024
From Benzinga
2 Dividend Stocks to Buy and Hold Forever
December 01, 2024
From Motley Fool
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
November 21, 2024
From Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
November 12, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.